Purified herpes simplex thymidine kinase Retrovector particles. I. In vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors.
Replication-defective, highly purified retroviral vectors (Retrovector), at titers of 10(8) colony forming units/mL, were prepared that conferred either beta-galactosidase or herpes simplex thymidine kinase (HSV-TK) activity. 9L gliosarcoma cells, transduced efficiently in vitro, were highly sensitive to ganciclovir (GCV). The mean frequency of in situ transduction, measured by flow cytometry of single-cell tumor suspensions isolated from rat brains, was 3.2 +/- 0.6%; similar assessments were made by staining of beta-galactosidase or by immunohistochemistry with anti-HSV-TK. In vitro HSV-TK-transduced and G418-selected 9L-TK gliosarcoma tumors treated with GCV were eradicated in approximately 53% of the animals (10/19) at day 26, however, 89% (17/19) histologically showed < 1% tumor volume. Histologic evaluation at day 26 of animals with established 9L tumors treated with intralesional injection of HSV-TK vector followed by GCV treatment showed that 29% (4/14) had no tumor; 50% (7/14) had < 1% tumor volume. Regression of tumors proceeded over the time since the complete rate was increased at day 60. Neither HSV-TK vector particles nor GCV alone altered the histological profile of 9L tumors, but substantial numbers of CD4+ and CD8+ lymphocytes infiltrated the tumors of animals treated with both. In cured animals, the former tumor bed contained cell debris, immune cells, and fibroblasts and was without damage to adjacent brain. The efficacy of suicide gene therapy for rat gliosarcoma using highly purified virion vectors approaches that of packaging cell lines.
Kruse
C A
CA
University of Colorado Health Services Center, Department of Immunology, Denver 80262, USA.
Roper
M D
MD
Kleinschmidt-DeMasters
B K
BK
Banuelos
S J
SJ
Smiley
W R
WR
Robbins
J M
JM
Burrows
F J
FJ
D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes; D002455:Cell Division / Q000235:genetics; D015774:Ganciclovir / Q000494:pharmacology; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D005839:Gentamicins / Q000494:pharmacology; D006583:Hexadimethrine Bromide / Q000737:chemistry / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D051381:Rats; D011919:Rats, Inbred Strains; D012190:Retroviridae / Q000235:genetics*; D018139:Simplexvirus / Q000201:enzymology; D013937:Thymidine Kinase / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D014161:Transduction, Genetic; D001616:beta-Galactosidase / Q000235:genetics / Q000378:metabolism
D000963:Antimetabolites; D005839:Gentamicins; D006583:Hexadimethrine Bromide; C010680:antibiotic G 418; D013937:Thymidine Kinase; D001616:beta-Galactosidase; D015774:Ganciclovir